Nursing Elites

1. In an acute mental health facility, a patient experiencing opioid withdrawal has a new prescription for Clonidine. What action should the nurse identify as the priority?

• A. Administer the Clonidine as prescribed.
• B. Provide ice chips to the patient.
• C. Educate the patient on Clonidine's effects.
• D. Obtain baseline vital signs.

Correct answer: D

Rationale: In this scenario, the priority action for the nurse is to obtain baseline vital signs. This is essential for establishing a baseline assessment, especially for a patient undergoing opioid withdrawal and starting a new medication like Clonidine. Monitoring vital signs is crucial for evaluating the patient's response to treatment and detecting any potential complications early on. Administering the medication, providing ice chips, and educating the patient on Clonidine's effects are important tasks but obtaining baseline vital signs takes precedence to ensure the patient's safety and proper management.

2. When starting therapy with trastuzumab, which finding should the nurse instruct the client to report?

• A. Dyspnea
• B. Constipation
• C. Tinnitus
• D. Dry mouth

Correct answer: A

Rationale: The correct answer is A: Dyspnea. Dyspnea can indicate pulmonary toxicity, a severe adverse effect of trastuzumab. It is crucial for the client to report any breathing difficulties promptly to ensure timely intervention and prevent further complications. Choices B, C, and D are incorrect because constipation, tinnitus, and dry mouth are not commonly associated with trastuzumab therapy and are not indicative of serious adverse effects that require immediate attention.

3. A healthcare professional is preparing to administer Pamidronate to a client who has bone pain related to cancer. Which of the following precautions should the healthcare professional take when administering pamidronate?

• A. Inspect the IV site for redness and irritation when changing the intravenous patch.
• B. Assess the IV site for thrombophlebitis frequently during administration.
• C. Instruct the client to sit upright or stand for 30 min following intravenous administration.
• D. Watch for manifestations of anaphylaxis for 20 min after intramuscular administration.

Correct answer: B

Rationale: Pamidronate is administered through intravenous (IV) infusion. As this medication can be irritating to veins, the healthcare professional should carefully assess the IV site for thrombophlebitis during administration to prevent potential complications. Choice A is incorrect as Pamidronate is not administered via intradermal patch. Choice C is incorrect as it does not relate to the administration of Pamidronate. Choice D is incorrect as Pamidronate is not administered intramuscularly.

4. A healthcare provider is assessing a client who takes Desmopressin for Diabetes Insipidus. For which of the following adverse effects should the healthcare provider monitor?

• A. Hypovolemia
• B. Hypercalcemia
• C. Agitation
• D. Headache

Correct answer: D

Rationale: The correct answer is D: Headache. Headache during desmopressin therapy can indicate water intoxication, which is a potential adverse effect. Desmopressin is a medication used to treat Diabetes Insipidus by reducing excessive urination and thirst. Monitoring for headaches is crucial as it can signal decreased sodium levels due to water retention, leading to water intoxication, which is a serious concern. Hypovolemia, hypercalcemia, and agitation are not typically associated with desmopressin therapy for Diabetes Insipidus.

5. While caring for a client receiving IV heparin, which of the following findings should the nurse identify as an adverse effect of this medication?

• A. Hypertension
• B. Hyperglycemia
• C. Thrombocytopenia
• D. Leukopenia

Correct answer: C

Rationale: Thrombocytopenia, a decrease in platelet count, is a known adverse effect associated with heparin therapy. It can lead to an increased risk of bleeding and should be closely monitored during treatment. Choices A, B, and D are incorrect. Hypertension is not typically associated with heparin use; hyperglycemia is not a common adverse effect of heparin; leukopenia is not a primary side effect of heparin therapy.

Similar Questions